IPSC Stock Overview
Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Century Therapeutics, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$3.14 |
52 Week High | US$5.51 |
52 Week Low | US$1.28 |
Beta | 1.34 |
1 Month Change | -37.20% |
3 Month Change | -17.37% |
1 Year Change | 1.95% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -86.25% |
Recent News & Updates
Recent updates
Century Therapeutics (NASDAQ:IPSC) Will Have To Spend Its Cash Wisely
Mar 06Century Therapeutics: More Attention Doesn't Mean You Should Buy Into INK Cell Therapy
Feb 01We're A Little Worried About Century Therapeutics' (NASDAQ:IPSC) Cash Burn Rate
Oct 23Century Therapeutics receives IND clearance for allogeneic cell therapy candidate
Aug 25Shareholder Returns
IPSC | US Biotechs | US Market | |
---|---|---|---|
7D | -21.7% | -5.0% | -3.5% |
1Y | 1.9% | -1.7% | 20.2% |
Return vs Industry: IPSC exceeded the US Biotechs industry which returned -1.8% over the past year.
Return vs Market: IPSC underperformed the US Market which returned 20.9% over the past year.
Price Volatility
IPSC volatility | |
---|---|
IPSC Average Weekly Movement | 12.5% |
Biotechs Industry Average Movement | 11.5% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.5% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: IPSC's share price has been volatile over the past 3 months.
Volatility Over Time: IPSC's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2018 | 159 | Brent Pfeiffenberger | www.centurytx.com |
Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors.
Century Therapeutics, Inc. Fundamentals Summary
IPSC fundamental statistics | |
---|---|
Market cap | US$237.88m |
Earnings (TTM) | -US$136.67m |
Revenue (TTM) | US$2.24m |
91.1x
P/S Ratio-1.5x
P/E RatioIs IPSC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
IPSC income statement (TTM) | |
---|---|
Revenue | US$2.24m |
Cost of Revenue | US$84.14m |
Gross Profit | -US$81.90m |
Other Expenses | US$54.77m |
Earnings | -US$136.67m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -2.11 |
Gross Margin | -3,664.56% |
Net Profit Margin | -6,115.12% |
Debt/Equity Ratio | 0% |
How did IPSC perform over the long term?
See historical performance and comparison